The Market's Weirdest Week: Geopolitics, GLP-1 Pills, and Bill Ackman's $64B Music Bet

---

The stock market is doing three completely different things at once, and nobody’s really talking about how they connect.

You’ve got Trump threatening Iran with civilization-ending consequences over the Strait of Hormuz. UnitedHealth surging while Nike bleeds. Used car prices hitting their highest point since summer 2023. Bill Ackman trying to buy Universal Music for $64 billion. Novo Nordisk’s new Wegovy pill drawing waves of patients. And somewhere in the chaos, prediction markets are blowing up so fast that House Democrats are asking regulators to panic.

This isn’t normal market noise. This is what happens when four different structural stories collide in the same week.

The Strait of Hormuz Isn’t Just Oil Anymore

Let’s start with the thing that’s supposed to scare everyone: Trump’s ultimatum about Iran and the Hormuz deadline. The Dow dropped ahead of it, which makes sense on the surface. Oil supply shock, inflation fears, traditional playbook.

But here’s what’s actually happening. The near closure of the Strait since the war began has already sent global energy prices soaring. That’s not a future scenario—that’s priced in. What traders are actually nervous about is volatility uncertainty. Do we get a negotiated settlement, a minor flare-up, or does this actually escalate?

The market hates three things: bad surprises, good surprises (trust me), and ambiguity. Right now we’re swimming in ambiguity. UnitedHealth surging while the Dow falls tells you something important: investors aren’t panicking about recession or systemic risk. They’re rotating. They’re picking winners and losers inside an uncertain regime.

Photo by Matheus Bertelli / Pexels

The Used Car Rip That Everyone’s Sleeping On

Used car prices just hit their highest point since summer 2023. That’s not a typo. That’s not a blip.

Think about what this means. Inflation’s supposed to be tamed. Supply chains are normalized. We should be seeing deflationary pressure in goods. Instead, used cars are appreciating like they’re a store of value.

My read: people are holding onto their vehicles longer because new car prices are still insane, and that’s creating artificial scarcity in the used market. But it also signals something deeper. Consumer balance sheets are weaker than headline numbers suggest. People aren’t trading up like they normally would in a healthy economy. They’re stretched, making do, and that’s keeping the used market tight.

This matters for auto stocks and for consumer discretionary more broadly. If people aren’t buying new, it’s not because they don’t want to—it’s because they can’t comfortably. That’s a warning sign dressed up as a price increase.

The GLP-1 Pill Revolution That’s Actually Happening

Novo Nordisk launched an oral version of Wegovy, and actual patients are taking it. This isn’t theoretical anymore.

Here’s what kills me about this: the pharmaceutical industry has been trying to solve weight loss for decades. Billions in R&D. Failed trials. Side effects. And then Novo just… makes a pill that works. Five patients spoke to CNBC about their early experiences, and they’ve got “varying initial experiences,” which is corporate speak for “some love it, some have issues.”

That’s actually fine. That’s how you build a market. You get the early adopters who tolerate some side effects because they get real results. Then you refine. Then you get the mainstream.

The economics here are staggering. A pill that works for weight loss doesn’t just shift market share in pharma. It creates an entirely new category of patient. How many people currently aren’t on GLP-1s because they’re squeamish about injections? Millions. Tens of millions globally.

My prediction: This is going to be bigger than everyone thinks, and it’s going to create secondary winners in everything from food companies to diabetes management to weight loss coaching apps. The direct pharma play is obvious. The ecosystem play is where the real money goes.

Photo by Markus Spiske / Pexels

Bill Ackman’s Bet That Smells Like Opportunity

Pershing Square just proposed a $64 billion acquisition of Universal Music. Ackman says the stock’s “languished” and that a merger can fix the underlying issues.

Let me be honest: I don’t fully understand what’s wrong with Universal Music that $64 billion fixes. The streaming economics are brutal for everyone in that industry. Artists want more cuts. Platforms want lower licensing fees. It’s structurally compressed.

But here’s what I notice: When Ackman makes a $64 billion unsolicited offer, the stock rises immediately. That tells you the market thinks there’s either (a) a genuine breakdown in management that an activist can fix, or (b) hidden value that a sophisticated buyer can extract. Probably both.

The risk is that Ackman overpays and then gets stuck in a 10-year legal/regulatory nightmare trying to actually integrate the deal. The opportunity is that he’s right and Universal’s catalog value is criminally underpriced.

I’m genuinely uncertain which way this goes. That’s the honest take.

The Prediction Market Thing Everyone’s Ignoring

House Democrats are asking regulators to crack down on prediction markets—specifically war bets on platforms like Kalshi and Polymarket.

This is going to sound weird, but this might be the most important story of the bunch. Prediction markets have exploded in popularity. They’re becoming real price discovery mechanisms for geopolitical events. That’s either awesome (efficient information aggregation) or terrifying (money flowing to people betting on civilian deaths) or both.

The regulatory instinct to shut this down is predictable and probably wrong. But the fact that it’s happening signals that prediction markets are now big enough to matter politically. They’re not cute anymore. They’re threats to narrative control.

What happens when you have millions of dollars flowing through markets that price Iran escalation differently than traditional financial markets? You get signal fragmentation. You get arbitrage opportunities. You get real traders potentially acting on information embedded in prediction market prices.

We’re in uncharted territory here, and regulators are panicking because they don’t understand it yet.

Photo by Markus Spiske / Pexels

What Connects All This

The real story is that we’re in a regime where traditional hedges don’t work anymore. Rates are higher. Oil could spike. Geopolitical risk is real and pricing-in sporadically. Healthcare bifurcation is real (UnitedHealth up, broader healthcare optionality matters more).

Structural stories—GLP-1 adoption, used car pricing, music industry consolidation—are running on parallel tracks from macro uncertainty. They’re not derivative of the Hormuz situation. They’re independent. That means they’ll create winners and losers regardless of what happens with Iran.

The Nike sell-off continues because the pressure on apparel margins is real. C.H. Robinson and ON Semiconductor are standouts because they’ve figured out how to operate in this regime. Advance Auto Parts beat earnings and still slid, which is the dumbest tell that the market cares less about beating numbers than about forward momentum and narrative.

What I’m Watching

• Trump-Iran deadline resolution vs. market repricing: If we get a deal or de-escalation, watch whether the Dow reverses and whether that signals a broader “risk-off” turning into “risk-on.” If it escalates, watch whether oil punches through $100 and whether that finally creates actual recessionary pressure.

• Novo Nordisk pill uptake trajectory: The first quarterly results showing oral Wegovy adoption rates will tell you if this is transformational or incremental. I’m watching for uptake as a percentage of total GLP-1 patients by Q2 2026.

• Pershing Square’s Universal Music gambit closing probability: This deal either closes in 18 months with regulatory approval or it becomes a three-year nightmare. Watch for SEC/DOJ signals on merger clearance by Q2 2026.

• Used car price momentum breaking: If used cars stay elevated through 2026, it’s a consumer balance sheet story. If they crack, it’s a warning signal about job market softening. Watch the monthly trend—any month-over-month declines two months in a row is actionable.

The market’s not confused. It’s just diversified across too many storylines at once. The traders who win are the ones who figure out which storyline actually moves their portfolio.